An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Organ donation registration can be completed through the Ohio Bureau of Motor Vehicles. Living donors can contact one of two ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...